HELIXMITH CO., LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4,015 KRW | +0.12% |
|
-5.08% | -34.93% |
| Apr. 25 | Helixmith Co., Ltd announced that it has received KRW 3.37919826 billion in funding | CI |
| Feb. 05 | Helixmith Co., Ltd announced that it expects to receive KRW 3.37919826 billion in funding | CI |
| Sales 2022 | 2.8B 2.05M | Sales 2023 | 4.2B 3.08M | Capitalization | 256B 188M |
|---|---|---|---|---|---|
| Net income 2022 | -43.54B -31.87M | Net income 2023 | -64.09B -46.91M | EV / Sales 2022 | 112 x |
| Net cash position 2022 | 83.39B 61.04M | Net cash position 2023 | 93.75B 68.62M | EV / Sales 2023 | 38.7 x |
| P/E ratio 2022 |
-9.14
x | P/E ratio 2023 |
-4
x | Employees | 61 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 71.77% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +0.12% | ||
| 1 week | -5.08% | ||
| Current month | -8.96% | ||
| 1 month | -12.62% | ||
| 3 months | -16.35% | ||
| 6 months | -13.47% | ||
| Current year | -34.93% |
1 week
3 975.00
4 235.00
1 month
3 975.004 750.00
Current year
3 250.007 440.00
1 year
3 250.009 100.00
3 years
3 250.0037 863.64
5 years
3 250.00148 436.36
10 years
3 250.00185 018.18
| Managers | Title | Age | Since |
|---|---|---|---|
Seung-Shin Yoo
CEO | Chief Executive Officer | 58 | - |
Sun-Young Kim
FOU | Founder | 68 | 96-11-20 |
Won-Ho Park
PSD | President | 66 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Sun-Young Kim
FOU | Founder | 68 | 96-11-20 |
Hoon-Shik Kim
BRD | Director/Board Member | 62 | - |
Seung-Shin Yoo
CEO | Chief Executive Officer | 58 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-22 | 4,015 | +0.12% | 49 403 |
| 24-05-22 | 4,010 | -0.50% | 73,738 |
| 24-05-21 | 4,030 | -1.23% | 85,083 |
| 24-05-20 | 4,080 | -1.81% | 117,773 |
| 24-05-17 | 4,155 | -1.07% | 59,884 |
End-of-day quote Korea S.E., May 22, 2024
More quotes
Helixmith Co Ltd, formerly ViroMed Co Ltd, is a Korea-based company mainly engaged in the development and sales of natural medicines and health functional foods. The Company operates its business through two segments. The Natural Products Business segment develops and sells raw materials for functional materials and health functional foods such as Alex, Murphine, and Nimosin. The New Biopharmaceutical Business segment develops diabetic neuropathy treatment, diabetic ischemic foot ulcer, amyotrophic lateral sclerosis treatment, ischemic heart disease, and anticancer treatment.
Sector
Food Processing
Calendar
2024-08-12
- Q2 2024 Earnings Release (Projected)
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -34.93% | 147M | |
| +15.09% | 8.35B | |
| +3.37% | 7.62B | |
| +1.45% | 6.01B | |
| -6.26% | 3.75B | |
| -9.86% | 3.7B | |
| -6.55% | 1.34B | |
| -28.83% | 1.13B | |
| +14.31% | 992M | |
| -10.78% | 925M |
- Stock Market
- Equities
- A084990 Stock
